A Single Digital Handheld Imaging Device For Use In Both Ophthalmology And Dentistry
Funder
National Health and Medical Research Council
Funding Amount
$431,221.00
Summary
Our aim is to produce and validate a single digital imaging device which can be used in ophthalmology (both for retinal and anterior segment imaging) and dentistry. This device will be low-cost, easy-to-operate and portable. Our planned development of the novel screening tool should help in bringing high quality, lower cost health care to those without easy access to it, firstly to residents of rural areas in Australia and then in developing countries in our region. This can be achieved by more ....Our aim is to produce and validate a single digital imaging device which can be used in ophthalmology (both for retinal and anterior segment imaging) and dentistry. This device will be low-cost, easy-to-operate and portable. Our planned development of the novel screening tool should help in bringing high quality, lower cost health care to those without easy access to it, firstly to residents of rural areas in Australia and then in developing countries in our region. This can be achieved by more efficient screening methods and redirecting resources to target those with treatable eye disease only. The detection process can be progressively transferred to less expensive health workers while ophthalmologist input can be redirected to monitoring the screening results and performing surgery. The dentists travel infrequently to rural and remote WA. If the dentist can pre plan their treatment then it will be more efficient and possible to treat more people at each visit to remote and rural WA. With the help of the proposed imaging device for dentistry, the nurses and other allied personnel should be able to send the digital images in advance to dentist over Internet and therefore help dentist pre-plan their treatment. As a result, improved dental care for rural, remote and underserved communities will occur.Read moreRead less
A ROBOTIC MICRO DRAINAGE SURGERY FOR GLAUCOMA (A BIOLOGICAL MICROFISTULA AND IMPLANTATION METHOD AND APPARATUS)
Funder
National Health and Medical Research Council
Funding Amount
$441,020.00
Summary
Glaucoma is a major cause of blindness in our community. We are developing a new surgical procedure to treat glaucoma. The technique is based on the implantation of a tiny drainage tube inside the eye. This allows the eye's natural fluid to escape at the required rate. Insufficient drainage, or over production of fluid in the eye's of glaucoma patients is responsible for the high pressures inside the eye that characterise this disease. A simple, safe, and reliable surgical procedure to lower int ....Glaucoma is a major cause of blindness in our community. We are developing a new surgical procedure to treat glaucoma. The technique is based on the implantation of a tiny drainage tube inside the eye. This allows the eye's natural fluid to escape at the required rate. Insufficient drainage, or over production of fluid in the eye's of glaucoma patients is responsible for the high pressures inside the eye that characterise this disease. A simple, safe, and reliable surgical procedure to lower intraocular pressure would be a major benefit to the almost 67 million glaucoma patients worldwide, and would relieve the current need for lifelong medication.Read moreRead less
RNA Interference In Model Systems Of Macular Degeneration.
Funder
National Health and Medical Research Council
Funding Amount
$166,500.00
Summary
Exudative age-related macular degeneration (AMD) is the most common cause of irreversible severe vision loss in the elderly, with an estimated 25-30 million people worldwide blind due to AMD. There is currently no standard treatment for AMD. A safe, specific and effective pharmacologic agent for AMD, therefore, has enormous therapeutic, social and economic benefits. AMD is underpinned by vascular leakiness and new blood vessel formation. We have demonstrated that Egr-1, a nuclear transcription f ....Exudative age-related macular degeneration (AMD) is the most common cause of irreversible severe vision loss in the elderly, with an estimated 25-30 million people worldwide blind due to AMD. There is currently no standard treatment for AMD. A safe, specific and effective pharmacologic agent for AMD, therefore, has enormous therapeutic, social and economic benefits. AMD is underpinned by vascular leakiness and new blood vessel formation. We have demonstrated that Egr-1, a nuclear transcription factor, plays a key regulatory role in a diverse array of angiogenic processes. In this project, we will use novel gene-targeting agents (Egr-1 siRNA) to provide preclinical proof-of principle evidence of their therapeutic potential in established animal models of AMD. These studies will pre-empt Phase IA safety trials in AMD patients.Read moreRead less
Web-based Multimedia Information Management System For Use In Remote Diagnosis Of Eye Diseases
Funder
National Health and Medical Research Council
Funding Amount
$196,000.00
Summary
Our aim is to develop a web-based multimedia information management system for use in remote diagnosis of eye diseases. The proposed system will provide medical advice and diagnosis, information and distance education for those working in health care as well as the community, computer-aided diagnosis and assistance in the operational and medical decision-making process. Less expensive health care personnel should be able to use the system with little training in remote and rural areas. Significa ....Our aim is to develop a web-based multimedia information management system for use in remote diagnosis of eye diseases. The proposed system will provide medical advice and diagnosis, information and distance education for those working in health care as well as the community, computer-aided diagnosis and assistance in the operational and medical decision-making process. Less expensive health care personnel should be able to use the system with little training in remote and rural areas. Significantly, the project should empower remote general doctors and nurses by proper access to expert advice, save many remote patients from unnecessary visits to specialist centres on the one hand and allow more proper diagnosis and intervention on the other. It has the potential for significant reductions in the cost of health care delivery, should strengthening the bond between medical services in remote and city areas, provide training and education of local GPs, nurses, health care workers and optometrists and provide web-based disease management systems will provide instant access to health care information. The outcomes of this project are potentially of great significance to remote and rural communities in Australia and around the world. There will be an enormous impact on current health care practices. Significantly, the project should empower remote general doctors and nurses by proper access to expert advice, save many remote patients from unnecessary visits to specialist centres on the one hand and allow more proper diagnosis and intervention on the other. It has the potential for significant reductions in the cost of health care delivery, should strengthening the bond between medical services in remote and city areas, provide training and education of local GPs, nurses, health care workers and optometrists and provide web-based disease management systems will provide instant access to health care information. The outcomes of this project are potentially of great significance to remote and rural communities in Australia and around the world. There will be an enormous impact on current health care practices.Read moreRead less
Novel System For Non-Invasive Delivery Of Drugs To The Interior Of The Eye
Funder
National Health and Medical Research Council
Funding Amount
$200,213.00
Summary
Age-related macular degeneration (AMD) is the leading cause of visual loss for adults in the developed world. Treatment is now by needle injection into the back of the eye, which is painful for the patient and is costly for the health-care system. Seagull Technology Pty Ltd has developed a non-invasive device for treating the back of the eye without the need for a needle injection. This project will test the new device in animals and then move to a first safety study for human AMD patients.
Development Of A Slit Scanning Laser Ophthalmoscope As A Screening Tool In Glaucoma Diagnostics
Funder
National Health and Medical Research Council
Funding Amount
$195,830.00
Summary
Glaucoma is typified by progressive optic disc cupping and loss of fibres with consequent characteristic field defects. Direct imaging of the retina and quantitative assessment of such images greatly increases early diagnosis of this blinding disease. The proposed device, a laser line scanning ophthalmoscope, could support non-invasive imaging to obtain 3-D information in a simple and cost effective way. This could provide objective clinical parameters to support the decision making process.
An Inside-out Approach To Muscosal Vaccination: MAdCAM Targeting
Funder
National Health and Medical Research Council
Funding Amount
$174,250.00
Summary
The mucosal surfaces are the entry site for many pathogens (eg. cholera, rotaviruses, helicobacter, SARS and sexually transmitted diseases including HIV infections). The ideal vaccine would elicit both systemic and mucosal immune response, enhancing immunity at this first line of defence. The oral route has formidable barriers to antigen uptake such as digestive enzymes, commensal microbes, mucous layers and gastric acid. Our strategy targets the vascular addressin found in immune tissues of the ....The mucosal surfaces are the entry site for many pathogens (eg. cholera, rotaviruses, helicobacter, SARS and sexually transmitted diseases including HIV infections). The ideal vaccine would elicit both systemic and mucosal immune response, enhancing immunity at this first line of defence. The oral route has formidable barriers to antigen uptake such as digestive enzymes, commensal microbes, mucous layers and gastric acid. Our strategy targets the vascular addressin found in immune tissues of the gut (called MAdCAM) so that the vaccine is linked to an antibody against MAdCAM. Thus for the first time we believe that a parenteral vaccine ie. injected im or iv (bypassing the oral barriers) can induce mucosal immunity.Read moreRead less
GM-CSF Regulation Of Preimplantation Embryo Development
Funder
National Health and Medical Research Council
Funding Amount
$481,320.00
Summary
Treatment of infertility using IVF technology has been enormously successful. However, there are major concerns regarding the high incidence of multiple pregnancies (caused by the transfer of more than one embryo) and the potential adverse health outcome of adults conceived from this technology. Multiple pregnancies place both mother and infant at enormous risks, with increased obstetrics care, prematurity, increased neonatal care and neurological disorders such as cerebral palsy. This can be ov ....Treatment of infertility using IVF technology has been enormously successful. However, there are major concerns regarding the high incidence of multiple pregnancies (caused by the transfer of more than one embryo) and the potential adverse health outcome of adults conceived from this technology. Multiple pregnancies place both mother and infant at enormous risks, with increased obstetrics care, prematurity, increased neonatal care and neurological disorders such as cerebral palsy. This can be overcome simply by the transfer of a single embryo. However, patient and clinical expectations are that single embryo transfer should be achieved with little to no reduction in pregnancy rate, and currently this is not possible because our methods for culturing embryos are inadequate. Studies in animals suggest that laboratory growth of mammalian embryos can lead to small-for-gestational age babies (even when the effect of multiple births is taken into consideration). This backed by recent studies which agree that babies born from IVF are smaller than expected. This might lead to health problems in later life, as smallness at birth is associated with higher risks of cardiovascular disease and diabetes, especially as age progresses beyond 40 years. However, the oldest IVF child is currently 23 years of age. Previously we have shown that a protein growth factor, called granulocyte-macrophage colony-stimulating factor (GM-CSF), found normally in the reproductive tract, has dramatic beneficial effects on human and mouse embryos grown in the laboratory. Furthermore, we have shown in mice that embryo exposure to GM-CSF alleviates the detrimental side effects of in vitro culture on foetal growth and body structure after birth. Our research is now focussed on understanding why this protein is beneficial to embryo growth and to test if we can increase pregnancy rates and produce normal healthy infants from the transfer of single embryos treated with GM-CSF.Read moreRead less
Development Fo A Novel Treatment For Asthma: The Identification Of Lead Small Molecule Antagonists Of The IL-13/IL-13 Re
Funder
National Health and Medical Research Council
Funding Amount
$99,750.00
Summary
In developed countries Asthma ranks among the most common chronic illnesses. Over two million Australians now have this condition and the cost to our community is estimated to be in excess of $720 million per annum. In 1996 researchers at The Walter and Eliza Hall Institute discovered a new member of the cytokine receptor family, IL-13Ra1, which further research has strongly implicated in the pathology of this disease. The main goal of the proposed research is to discover small molecule antagoni ....In developed countries Asthma ranks among the most common chronic illnesses. Over two million Australians now have this condition and the cost to our community is estimated to be in excess of $720 million per annum. In 1996 researchers at The Walter and Eliza Hall Institute discovered a new member of the cytokine receptor family, IL-13Ra1, which further research has strongly implicated in the pathology of this disease. The main goal of the proposed research is to discover small molecule antagonists of IL-13Ra1 and to identify those suitable for development as novel asthma therapeutics.Read moreRead less